PDF(Pubmed)
Abstract：
Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64+HLADRlow granulocytes, showed significant correlations with B and T cell responses induced by vaccination. Our findings suggest the potential role of myeloid cells in cellular and humoral responses following vaccination in DMT-treated patients with neuroimmunological diseases.
摘要：
疾病修饰疗法（DMT）广泛用于神经免疫疾病，例如多发性硬化症（MS）和视神经脊髓炎谱系障碍（NMOSD）。尽管已知这些治疗会使患者容易感染并影响他们对疫苗的反应，关于DMT对髓系细胞区室的影响知之甚少。在这项研究中,我们使用质量细胞仪检测未治疗和接受治疗的MS(n=39)或NMOSD(n=23)患者的先天免疫系统DMT相关变化.我们还研究了骨髓细胞表型的变化与对同源原发性，次要,和第三次SARS-CoV-2mRNA疫苗接种。多个DMT相关骨髓细胞簇,特别是CD64+HLADRlow粒细胞，与疫苗接种诱导的B细胞和T细胞反应显着相关。我们的发现表明，在DMT治疗的神经免疫疾病患者中，骨髓细胞在接种疫苗后的细胞和体液反应中的潜在作用。
